Junto Health

FierceBiotech | January 21, 2020

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get in on this burgeoning new trend. “These solutions are designed to reduce time and risk for sponsors at each phase and across the full continuum of their therapy development needs in one of the industry’s fastest-growing segments,” Covance, the CRO unit of diagnostics giant LabCorp, said in a statement. This follows the first CAR-T cell therapy approvals from Novartis ...

European Biotechnology | February 17, 2020

PharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer). The PDUFA date was set for August 16, 2020 by the US Food and Drug Administration (FDA) for lurbinectedin as second-line treatment for patients with SCLC who relapsed following platium-based chemotherapy. The synthetic drug developed by PharmaMar SA (Madrid, Spain) and exclusively licenced by Jazz Pharmaceuticals plc (Dublin, Ireland) in December 2019 works b...

INDUSTRIAL IMPACT

Mind Medicine (MindMed) Inc. | December 30, 2021

Mind Medicine Inc. a leading biotech company developing psychedelic-inspired therapies, announced that its Chief Technology Officer, Bradford Cross, has transitioned from his role. "On behalf of the Board of Directors and Executive team, I would like to thank Bradford for his contributions to the Company and wish him all the best in his future endeavors. We remain dedicated to advancing our pipeline and ongoing digital therapeutics platform forward under...

CELL AND GENE THERAPY

Enara Bio | December 09, 2020

Enara Bio, a biotechnology organization utilizing its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver focused on cancer immunotherapies, announces its extension and move to the new Bellhouse Building at The Oxford Science Park. Enara Bio's move from the Oxford BioEscalator to one of the UK's biggest biomedical advancement habitats is in anticipation of its future development and desire to change malignancy care. The devoted exploration offi...